Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(23):1711; doi:10.1093/jnci/dji452
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Whitworth, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Whitworth, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

MEMO TO THE MEDIA

Press Release

Dose-Dense Chemotherapy for Early Breast Cancer Found Safe, Similar to Standard Regimen

Ariel Whitworth

jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute

The first 10% of the full text of this article appears below.

Biweekly chemotherapy treatment—a dose-dense regimen—for patients with early-stage breast cancer was found to be as safe as treatment administered every third week; however, the dose-dense regimen did not result in improvements in recurrence or survival, according to a study in the December 7 issue of the Journal of the National Cancer Institute.

In standard adjuvant therapy for . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?